|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: METTL13 |
Gene summary for METTL13 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | METTL13 | Gene ID | 51603 |
| Gene name | methyltransferase 13, eEF1A lysine and N-terminal methyltransferase | |
| Gene Alias | 5630401D24Rik | |
| Cytomap | 1q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q8N6R0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51603 | METTL13 | P2T-E | Human | Esophagus | ESCC | 3.61e-17 | 2.92e-01 | 0.1177 |
| 51603 | METTL13 | P4T-E | Human | Esophagus | ESCC | 2.49e-20 | 4.95e-01 | 0.1323 |
| 51603 | METTL13 | P5T-E | Human | Esophagus | ESCC | 4.92e-15 | 2.31e-01 | 0.1327 |
| 51603 | METTL13 | P8T-E | Human | Esophagus | ESCC | 3.29e-10 | 1.28e-01 | 0.0889 |
| 51603 | METTL13 | P9T-E | Human | Esophagus | ESCC | 6.92e-09 | 1.87e-01 | 0.1131 |
| 51603 | METTL13 | P10T-E | Human | Esophagus | ESCC | 1.20e-11 | 1.51e-01 | 0.116 |
| 51603 | METTL13 | P11T-E | Human | Esophagus | ESCC | 4.86e-10 | 2.76e-01 | 0.1426 |
| 51603 | METTL13 | P12T-E | Human | Esophagus | ESCC | 7.38e-12 | 1.56e-01 | 0.1122 |
| 51603 | METTL13 | P15T-E | Human | Esophagus | ESCC | 9.44e-07 | 2.09e-01 | 0.1149 |
| 51603 | METTL13 | P16T-E | Human | Esophagus | ESCC | 1.39e-16 | 2.54e-01 | 0.1153 |
| 51603 | METTL13 | P20T-E | Human | Esophagus | ESCC | 1.13e-16 | 2.20e-01 | 0.1124 |
| 51603 | METTL13 | P21T-E | Human | Esophagus | ESCC | 1.77e-15 | 1.45e-01 | 0.1617 |
| 51603 | METTL13 | P22T-E | Human | Esophagus | ESCC | 3.01e-14 | 1.62e-01 | 0.1236 |
| 51603 | METTL13 | P23T-E | Human | Esophagus | ESCC | 2.55e-14 | 4.02e-01 | 0.108 |
| 51603 | METTL13 | P24T-E | Human | Esophagus | ESCC | 1.18e-10 | 1.77e-01 | 0.1287 |
| 51603 | METTL13 | P26T-E | Human | Esophagus | ESCC | 5.17e-15 | 2.86e-01 | 0.1276 |
| 51603 | METTL13 | P27T-E | Human | Esophagus | ESCC | 1.28e-11 | 1.39e-01 | 0.1055 |
| 51603 | METTL13 | P28T-E | Human | Esophagus | ESCC | 3.40e-16 | 3.09e-01 | 0.1149 |
| 51603 | METTL13 | P30T-E | Human | Esophagus | ESCC | 8.50e-12 | 3.32e-01 | 0.137 |
| 51603 | METTL13 | P31T-E | Human | Esophagus | ESCC | 7.76e-14 | 1.75e-01 | 0.1251 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| METTL13 | SNV | Missense_Mutation | rs763718769 | c.563A>C | p.Asn188Thr | p.N188T | Q8N6R0 | protein_coding | tolerated(0.54) | benign(0) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| METTL13 | SNV | Missense_Mutation | novel | c.1112A>T | p.Gln371Leu | p.Q371L | Q8N6R0 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-AC-A5EH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| METTL13 | SNV | Missense_Mutation | c.959N>C | p.Gly320Ala | p.G320A | Q8N6R0 | protein_coding | deleterious(0.01) | benign(0.382) | TCGA-EA-A1QT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| METTL13 | SNV | Missense_Mutation | novel | c.1682N>C | p.Gly561Ala | p.G561A | Q8N6R0 | protein_coding | tolerated(0.79) | benign(0) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| METTL13 | SNV | Missense_Mutation | c.281N>A | p.Arg94Gln | p.R94Q | Q8N6R0 | protein_coding | tolerated(0.14) | benign(0.357) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| METTL13 | SNV | Missense_Mutation | c.1882N>A | p.Ala628Thr | p.A628T | Q8N6R0 | protein_coding | tolerated(0.54) | benign(0.005) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| METTL13 | SNV | Missense_Mutation | novel | c.1967N>T | p.Pro656Leu | p.P656L | Q8N6R0 | protein_coding | deleterious(0.04) | benign(0.005) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| METTL13 | SNV | Missense_Mutation | novel | c.226N>G | p.Asn76Asp | p.N76D | Q8N6R0 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| METTL13 | SNV | Missense_Mutation | novel | c.1301N>T | p.Ser434Phe | p.S434F | Q8N6R0 | protein_coding | tolerated(0.52) | benign(0.299) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| METTL13 | SNV | Missense_Mutation | rs763335545 | c.232G>A | p.Asp78Asn | p.D78N | Q8N6R0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |